Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06892678 · ClinicalTrials.gov registry record · Phase 1
DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma
A Phase 1 study of Osteosarcoma Recurrent and Ewing's Tumor Recurrent, sponsored by Montefiore Medical Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT06892678 is a Phase 1 study of Osteosarcoma Recurrent and Ewing's Tumor Recurrent that is actively recruiting participants, run by Montefiore Medical Center. The registered enrollment target is 15 participants, below the 39-participant average among 4 other Osteosarcoma Recurrent trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06892678, a Phase 1 study of Osteosarcoma Recurrent and Ewing's Tumor Recurrent, is actively recruiting participants, sponsored by Montefiore Medical Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the feasibility of administering DFMO to patients with relapsed Ewing sarcoma and osteosarcoma who have completed all planned therapy and have no evidence of disease.
Conditions Studied
Interventions
- DRUG DFMO
Study Locations (1)
New York
- Montefiore Medical Center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2025-04-07 |
| Est. Completion | 2030-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06892678
The ClinicalTrials.gov registry entry for NCT06892678 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 39-participant average among 4 other Osteosarcoma Recurrent trials with a reported enrollment target (62% lower). The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Osteosarcoma Recurrent appearing as the primary indexed condition, and to 1 intervention - of which DFMO is the first listed.
NCT06892678 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06892678 about?
NCT06892678 is a clinical study titled "DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma". The purpose of this study is to determine the feasibility of administering DFMO to patients with relapsed Ewing sarcoma and osteosarcoma who have completed all planned therapy and have no evidence of disease.
What is the current status of trial NCT06892678?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2025-04-07. Estimated completion is 2030-04.
What conditions does trial NCT06892678 study?
This clinical trial studies the following conditions: Osteosarcoma Recurrent, Ewing's Tumor Recurrent.
What interventions are being tested in trial NCT06892678?
The interventions under investigation include: DFMO (DRUG).
Who is sponsoring clinical trial NCT06892678?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06892678 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteosarcoma Recurrent
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma
RECRUITING · Phase 1
-
Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
ACTIVE NOT RECRUITING · Phase 1
-
Olaparib With Ceralasertib in Recurrent Osteosarcoma
ACTIVE NOT RECRUITING · Phase 2
-
SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.